was estimated to be at most 30% of the butyrate production by mixed fecal microbes, which suggested that more butyrate is produced by microbes other than B. fibrisolvens in the intestines. Addition of B. fibrisolvens ATCC19171 (type I) to a culture of mixed fecal microbes increased butyrate production, and OB156 (type IIb) increased lactate production. When both the types were added, both the products were increased. Thus, introduction of both the types of B. fibrisolvens as a probiotic may increase butyrate and lactate production in the large intestine, which is possibly beneficial for the maintenance or improvement of the health of dogs and cats.
Introduction
Volatile fatty acids (VFA) produced by intestinal microbes have specific effects on colonic function and health (Cummings and MacFarlane, 1991; Szylit and Andrieux, 1993) . Butyrate in particular plays an important role in the metabolism and normal development of colonic epithelial cells, and has been implicated in protection against cancer and ulcerative colitis (Hague et al., 1997) . Butyrate is preferentially transported by gut epithelial cells (Delzenne and Roberfroid, 1994) , and utilized as a preferred energy source rather than sugars in colonocytes (Cummings, 1981; Roediger, 1980) . In addition, butyrate has been shown to exert direct effects on gene expression in mammalian cells through histone hyperacetylation and through interaction with butyrate response elements upstream of some genes (Csordas, 1995; Tran et al., 1998) .
It is thus conceivable that butyrate acts as an important factor in the maintenance of colonic health in dogs and cats, and it is desirable to augment butyrate production by intestinal microbes. Butyrate production can be increased by increasing the numbers of butyrateproducing bacteria, or by controlling the fermentation of butyrate-producing bacteria so as to increase butyrate production.
Butyrivibrio fibrisolvens, a predominant butyrate-producing bacterium in the rumen (Stewart et al., 1997) , is reported to have been isolated from human feces (Rumney et al., 1995) . No report is available at present on the presence of B. fibrisolvens in the digestive tract of dogs or cats, but it is possible that this bacterium colonizes in the intestines of dogs and cats. Butyrate production in the intestines may be increased by stimulating the growth of B. fibrisolvens, or by introducing B. fibrisolvens as a probiotic.
Strains of B. fibrisolvens are divided into two groups based on their fermentation products: One group (type I) mainly produces butyrate and formate, producing little lactate, while the other group (type IIb) produces lactate as a major fermentation product, and formate, acetate, and butyrate as minor products (Shane et al., 1969) . The type I strain, such as ATCC19171 (DiezGonzalez et al., 1999) , may be effective to increase butyrate production, and the type IIb strain, such as OB156 (Diez-Gonzalez et al., 1999) , may be helpful to increase lactate production. Since lactate production in the large intestine is also important to reduce pH, it may be beneficial to utilize both the types of B. fibrisolvens. However, there may be an antagonistic relationship between the two types. Bacteriocin produced by one strain of B. fibrisolvens has been reported to inhibit the growth of the other strains (Kalmokoff and Teather, 1997) .
On the other hand, B. fibrisolvens has long been known to isomerize linoleic acid to conjugated linoleic acid (CLA) (Kepler et al., 1966) , which has recently attracted considerable attention because of its potentially beneficial effects. CLA has been shown to inhibit chemically induced tumors (Ha et al., 1990; Ip et al., 1991) , prevent atherosclerosis (Nicolosi et al., 1997) , reduce body fat and increase muscle mass (Chin et al., 1992) , improve hyperinsulinemia (Houseknecht et al., 1998) , and improve immune activity (Cook et al., 1993; Miller et al., 1994) . Stimulation of the growth, or introduction as a probiotic, of B. fibrisolvens may increase CLA production in the gut.
For these reasons, we examined whether B. fibrisolvens is present in dog and cat feces, and estimated its numbers in feces by competitive PCR. We also examined the contribution of B. fibrisolvens in feces to butyrate production by mixed fecal microbes. In addition, we tested the effects of the addition of B. fibrisolvens on butyrate and lactate production in cultures of mixed fecal microbes. These bacteria were grown in batch culture with 120-ml serum vials as described previously (Asanuma and Hino, 1997) . The growth medium consisted of clarified rumen fluid (Hino et al., 1992) and a basal medium (1 : 3) containing 0.45 (g/L) of K 2 HPO 4 , 0.45 of KH 2 PO 4 , 0.9 of (NH 4 ) 2 SO 4 , 0.9 of NaCl, 0.12 of CaCl 2 · 2H 2 O, 0.19 of MgSO 4 · 7H 2 O, 1.0 of Trypticase (BBL; Becton Dickinson, Cockeysville, MD, USA), 1.0 of yeast extract (Difco Laboratories, Detroit, MI, USA), 3.0 of glucose, and 0.6 of cysteine · HCl (pH 6.9). Cultures were incubated in triplicate, maintaining the pH between 6.5 and 7.0 (Asanuma and Hino, 1997) , until the late-log growth. Cell growth was estimated by measuring the optical density at 600 nm.
Materials and Methods

Bacterial
When B. fibrisolvens was added to cultures of mixed fecal microbes, cells of B. fibrisolvens grown until the late-log stage were collected in an anaerobic glove box and centrifuged (20,000ϫg, 10 min). The pellet was then resuspended in a basal medium, and the cell suspension was inoculated.
Sources and culture conditions of fecal microbes. Freshly voided feces were collected from various breeds of 20 female and 17 male healthy dogs, whose ages ranged from 2 months to 13 years. Feces were also collected from various breeds of healthy cats (15 each of the female and male, 2 months to 5 years old). Fecal samples were collected twice a week from each animal for 2 weeks. These animals were fed commercial diets. None of the animals received any antibiotic or other medicine for at least a month prior to sampling.
A fecal sample used for culture as an inoculum was taken from a dog whose feces contained the largest number of B. fibrisolvens. The sample was immediately put into a vial on ice under a stream of CO 2 , and subjected to experiments within a day. Samples for DNA to estimate cell numbers of B. fibrisolvens were cooled on ice, and then stored at Ϫ80°C.
The fecal sample for inoculation was suspended in 10 volumes of dilution buffer, which contained 0.45 (g/L) of K 2 HPO 4 , 0.45 of KH 2 PO 4 , 0.9 of (NH 4 ) 2 SO 4 , 0.9 of NaCl, 0.12 of CaCl 2 · 2H 2 O, 0.19 of MgSO 4 · 7H 2 O, and 0.6 of cysteine · HCl (pH 6.9). The suspensions were mixed with a growth medium (1 : 5) under O 2 -free CO 2 using a blender. The mixture was anaerobically transferred to 120-ml serum vials (60 ml/vial). Cultures of mixed fecal microbes were incubated as described above, except that glucose in the growth medium was replaced by dextrinized potato starch.
When the contribution of B. fibrisolvens to total butyrate production by mixed fecal microbes was estimated, fecal suspension was boiled for 20 min to kill the microbes. A cell suspension of B. fibrisolvens OB156 (type IIb) was added to the culture incubated with the boiled feces so that the number was equal to the estimated number of the type IIb B. fibrisolvens in the feces.
Effect of the addition of B. fibrisolvens on butyrate production by mixed fecal microbes was examined under similar incubation conditions. In this case, ATCC19171 (type I) and/or OB156 were added to cultures at the levels indicated in Table 4 .
Determination of fermentation products. For the determination of organic acids, cultures were deproteinized with 10% sulfosalicylic acid by centrifugation (20,000ϫg, 10 min), and then analyzed by HPLC as described previously (Hino et al., 1991) .
Extraction of total DNA. Total DNA was extracted from feces and bacteria by the method of Purdy et al. (1996) as follows: Cells were disrupted in 1% SDS by shaking with glass beads, and extracted with phenol. The extracted DNA was cleaned up with HTP (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and Sephadex G-75 (Bio-Rad). Unless otherwise stated, DNA was extracted in triplicate from each sample. The concentration and purity of the DNA were determined spectrophotometrically at 260 and 280 nm with a Genequant II (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA), and 1 ng of the DNA was subjected to competitive PCR.
PCR amplification of 16S rDNA. Two sets of primer pairs were used for the amplification of 16S rDNA of B. fibrisolvens. One primer pair was targeted to 16S rDNA of B. fibrisolvens OB156 (type IIb): A primer was ACG ATG TTG CAT GAC AAC GTG (Probe-156), which was shown to be specific to the sequence of the type IIb (Forster et al., 1997; Kobayashi et al., 2000) . Another primer was CAA CTG CTG CCT CCC GTA (BfR). Another primer pair was designed to amplify 16S rDNA of B. fibrisolvens ATCC19171 (type I). The primers were BfR and CGG AGT TAT TCG CTG ATG (BfF). The specificity of the primers was confirmed by searching the PROBE CHECK program of the Ribosomal Database Project (Olsen et al., 1992) and the BLAST facility at the National Center for Biotechnology. The PCR products from OB156 and ATCC19171 were 176 and 308 bp, respectively.
PCR for the type IIb was carried out with TaKaRa Ex Taq polymerase (TaKaRa Shuzo Co., Ohtsu, Japan) as follows: Denaturated at 94°C for 3 min, followed by 30 cycles of denaturation at 94°C for 30 s, annealed at 52°C for 30 s, and extended at 72°C for 30 s, with the final cycle being at 72°C for 3 min. In PCR for the type I, annealing temperature was changed from 52°C to 49°C. The PCR products were electrophoresed with agarose gel, stained with ethidium bromide, and visualized by UV transillumination.
Construction of internal control DNA. The 176-bp PCR product from the chromosomal DNA of OB156 was blunted by T4 DNA polymerase, and integrated into a plasmid vector, pUC 18 (Toyobo Inc., Tokyo, Japan). The plasmid containing the 176-bp PCR product was digested with Acc II and Hae III, and religated with T4 DNA ligase (Toyobo) under the conditions recommended by the supplier. These plasmids were separated by agarose gel electrophoresis, and a plasmid deleting a 97-bp Acc II-Hae III fragment was extracted from the gel. The plasmid was amplified by PCR with Probe-156 and BfR. The PCR product (79 bp) was purified with a QIAquick PCR purification kit (Qiagen GmbH, Hilden, Germany), and used as an internal control for competitive PCR.
Similarly, the 308-bp PCR product from ATCC19171 was cloned, digested with Acc II, and religated, because the 308-bp product contained two Acc II sites. The plasmid deleting a 117-bp Acc II fragment was amplified by PCR with BfF and BfR, and the product was used as an internal control.
Quantification of PCR products. After elec-trophoresis, the PCR products in the gel were quantified using a Fluor-S Multi Imager (Bio-Rad). The amounts of the competitors added and the ratios of the amplified target DNA to the amplified competitor were plotted on log/log scale, and the amounts of target DNA were estimated by interpolation with calculated regression equations. Evaluation of data. Data were analyzed by the Tukey's test or by Student's t-test using the SigmaStat Statistical Analysis System (Jandel Scientific, San Rafael, CA, USA).
Results
PCR amplification of target DNA with internal control DNA
When the genomic DNA from OB156 was amplified by PCR with a primer pair, BfR and BfF, no product was detected even at an annealing temperature of 42°C (data not shown). Similarly, the DNA from ATCC19171 was not amplified when a primer pair, Probe-156 and BfR, were used. No amplicon was detected when the DNA extracted from the ruminal and intestinal bacteria described in MATERIALS AND METHODS, other than B. fibrisolvens, was used as templates. Even the DNA from C. proteoclasticum, whose 16S rDNA is phylogenetically close to that of ATCC 19171 (Reilly and Attwood, 1998), was not amplified by PCR with BfF and BfR. These results strongly suggest that each primer pair is specific to ATCC19171 or OB156.
The log plot of the amount of amplified target DNA against the amount of amplified internal control DNA was linear between 0.005 and 200 ng for the type IIb, and between 0.01 and 180 ng for the type I. These values corresponded to 2.1ϫ10 3 to 8.0ϫ10 7 cells and 3.0ϫ10 4 to 6.8ϫ10 7 cells, respectively (data not shown). When competitive PCR was carried out with graded amounts of B. fibrisolvens DNA, addition of the DNA from fecal samples did not affect the gradient of the standard curve (data not shown). This result suggests that no substance in the feces interfered with PCR.
Numbers of B. fibrisolvens in the feces of dogs and cats
Detection frequency of B. fibrisolvens type IIb in fecal samples is shown in Table 1 . The percentage of dogs that harbored the type IIb strains was 65%; 70% for the male, 59% for the female, 73% for dogs below the age of 2 years, and 53% for dogs above 2 years. The percentage of cats having the type IIb strains was 47%; 53% for the male, 40% for the female, 53% for cats below 2 years, and 36% for cats above 2 years.
Total cell numbers of the type IIb per g of feces (dry weight) varied from 2.4ϫ10 3 to 9.0ϫ10 5 for dogs and from 1.7ϫ10 4 to 6.2ϫ10 5 for cats (Table 2) . On average, 10 5 cells were present in 1 g of dry feces. However, no type I strain was detected in any of the feces tested (less than 6.0ϫ10 4 cells per g of dry feces).
Contribution of B. fibrisolvens to butyrate production by fecal microbes
No butyrate was produced by mixed fecal microbes that had been boiled for 20 min, but 5.2 mM butyrate was produced when OB156 was added at the level present in the feces (Table 3 ). The amount of butyrate produced by added OB156 was 30% of the amount produced by intact fecal microbes (17.4 mM). Addition of OB156 to intact feces increased butyrate production to 130% (23.2 mM) of the amount produced by intact fecal microbes. Effects of the addition of B. fibrisolvens on butyrate and lactate production by mixed fecal microbes Addition of ATCC19171 to cultures of mixed fecal microbes from a dog significantly increased butyrate production (Table 4) . Formate production was also increased, which suggests that B. fibrisolvens actually took part in starch fermentation, because butyrate production accompanies formate production in this organism. When 4-fold more cells were added, butyrate production was further increased. On the contrary, lactate production was decreased by the addition of ATCC19171, probably because B. fibrisolvens competed with lactate-producing bacteria for starch.
As expected, effect of the addition of OB156 on butyrate production was smaller than the effect of ATCC19171 (Table 4) . However, when added at a high level (4ϫ10 5 /ml), butyrate production was increased.
Contrary to the case of ATCC19171, lactate production was increased by the addition of OB156. Simultaneous addition of both the strains (1 : 1; total number, 4ϫ10 5 /ml) increased both butyrate and lactate, although the increase in each of the products was less than the increase brought about by each strain alone (Table 4) . Similar trend was observed when only B. fibrisolvens was cultured (Table 5 ). The amounts of butyrate and lactate produced in a coculture of ATCC19171 and OB156 were nearly the mean values for monocultures of each strain.
Discussion
B. fibrisolvens type IIb was found in feces of dogs and cats at levels of 10 4 -10 6 cells per g of feces (dry weight), although 35% of the dogs and 53% of the cats did not have B. fibrisolvens (Tables 1 and 2 ). B. fibrisolvens was present in younger animals more frequently than in older animals (Table 1) . However, type I was not detected from any dogs and cats tested, which suggests that the type I does not generally inhabit the intestines of dogs and cats, or if it does, the numbers are very small. Butyrate production by the type IIb in dog feces was estimated to be at most 30% of the butyrate production by mixed microbes in dog feces ( Table 3 ), suggesting that more butyrate is produced by microbes other than B. fibrisolvens in the dog intestines. Since the cell numbers of B. fibrisolvens were generally smaller in cat feces than in dog feces, contribution of B. fibrisol- 2) The type I was less than 3ϫ10 4 /ml and the type IIb was 1ϫ10 5 /ml. a-e Means within a column in each block with no common superscript letters differ (pϽ0.01, nϭ3). vens to total butyrate production in the intestines is presumed to be smaller in cats than in dogs. Since Clostridium and Eubacterium are known as major butyrate-producing bacteria in human feces (Barcenilla et al., 2000; Sharp and Macfarlane, 2000) , these bacteria may be predominant butyrate-producing bacteria also in dogs and cats. Butyrate-producing Clostridium is probably more predominant than butyrate-producing Eubacterium (Sharp and Macfarlane, 2000) . Since Clostridium is generally considered to have unfavorable effects on the host, it is desirable to suppress Clostridium and stimulate the growth of B. fibrisolvens. To increase butyrate production in the intestines, introduction of B. fibrisolvens as a probiotic must be beneficial.
As a probiotic, the type I is more desirable than the type IIb in that the former produces much more butyrate than the latter. Since growth rate was not different between ATCC19171 and OB156 (data not shown), more butyrate should be produced by the type I than the type IIb. In fact, addition of ATCC19171 to a culture of mixed fecal microbes increased butyrate production (Table 4) .
On the other hand, lactate production was decreased by the addition of ATCC19171 and increased by OB156 (Table 4) . Lactate production in the large intestine is important to keep the environment at acidic pH, which may protect the proliferation of pathogenic bacteria. In this respect, introduction of the type IIb such as OB156 is more beneficial.
Simultaneous addition of ATCC19171 and OB156 increased both butyrate and lactate (Table 4 ). The amounts of butyrate and lactate produced in a coculture of both the strains were nearly the mean values for monocultures of each strain (Table 5) , and the growth in coculture was not different from the growth of each strain in monoculture (data not shown). These observations indicate that there is no antagonism between the two strains.
Therefore, it may be desirable to introduce ATCC19171 and OB156 to the intestines of animals. However, whether B. fibrisolvens grows also in vivo remains to be examined. One of the important problems is an energy supply. Starch was used in this study, but little starch is usually available in the large intestine. Resistant starch that escapes from digestion in the upper digestive tract may be present in the large intestine. Both ATCC19171 and OB156 are able to utilize starch, indicating that these strains have a-amylase.
However, it is unknown whether B. fibrisolvens is able to degrade resistant starch; i.e., it is uncertain whether B. fibrisolvens has a debranching enzyme to cleave a-1,6-glucoside bond.
It has been reported that cecal butyrate production was enhanced by feeding rats resistant starch (Blay et al., 1999) . However, starch content in commercial diets for dogs and cats is generally low. Animals do not secrete any enzyme to digest fiber, implying that all dietary fiber flows to the large intestine. Since B. fibrisolvens is able to utilize xylan, supplying a diet containing xylan may support the growth of B. fibrisolvens.
In conclusion, introduction of both the types of B. fibrisolvens as a probiotic, in combination with a diet containing xylan, may be beneficial for the maintenance or improvement of the health of dogs and cats. Whether or not this idea is practicable remains to be studied.
